Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Defining Predictors of Radiological Transmural Response to Vedolizumab in Small Bowel Crohn's Disease Through Serum Proteomic Biomarkers

NCT03142321 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT03142321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03142321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Defining Predictors of Radiological Transmural Response to Vedolizumab in Small Bowel Crohn's Disease Through Serum Proteomic Biomarkers
Lead sponsor
Washington University School of Medicine
Phase
Phase 4
Overall status
Completed
Start date
June 8, 2018
Completion date
October 28, 2024
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease of small intestine